| Second Vasovagal Pacemaker Study (VPS II): rationale, design, results, and implications for practice and future clinical trials. | |
| | |
MedLine Citation:
|
PMID: 15071266 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Vasovagal syncope causes substantial morbidity. Various medications have been studied with goals of reducing event-rates and improving quality of life. Results have been mixed, with few drugs demonstrating benefit. Bradycardia usually accompanies vasovagal syncope during positive tilt table tests, and is recorded in up to 50% of clinical syncopal spells documented on electrocardiographic loop recorders. These findings form the rationale for studies of the effectiveness of pacing in preventing vasovagal syncope. Three historically controlled trials of permanent pacing showed that 80-90% of patients had a marked symptomatic improvement, with 90-95% reductions in the number of expected syncopal spells. Subsequently three open-label trials randomized a total of 189 patients evenly to medical therapy or pacemakers in trials that used the proportion of patients with recurrent syncope as the primary outcome. They showed relative risk reductions of 80-87% in the paced patients. However these early studies were not blinded, raising concern about the possible role of a significant placebo effect. This issue was addressed in the recent Second Vasovagal Pacemaker Study (VPS II), in which 100 patients received pacemakers. They then were randomized to pacing with rate drop sensing, or sensing without pacing. The cumulative risk of syncope at 6 months was 40% for the control group and 31% for the actively paced group. The relative risk reduction in time to syncope with pacing was 30% (1 p = 0.14). The AHA/ACC guidelines about pacing and vasovagal syncope should be reassessed. Future clinical trials of therapies for vasovagal syncope should be randomized and placebo-controlled. |
| | |
Authors:
|
Robert Sheldon; Stuart Connolly; |
Related Documents
:
|
15826276 - Isotretinoin (13-cis-retinoic acid) associated atrial tachycardia. 1136936 - Electrophysiologic effects of isoproterenol on cardiac conduction system in man. 7515706 - Magnesium and arrhythmias after coronary artery bypass surgery. 10421596 - Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias afte... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Cardiac electrophysiology review Volume: 7 ISSN: 1385-2264 ISO Abbreviation: Card Electrophysiol Rev Publication Date: 2003 Dec |
Date Detail:
|
Created Date: 2004-04-08 Completed Date: 2004-08-26 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9708907 Medline TA: Card Electrophysiol Rev Country: United States |
Other Details:
|
Languages: eng Pagination: 411-5 Citation Subset: IM |
Affiliation:
|
Cardiovascular Research Group, University of Calgary, Calgary, Alberta, Canada. sheldon@ucalgary.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bradycardia
/
prevention & control Cardiac Pacing, Artificial* / methods Humans Multicenter Studies as Topic Pacemaker, Artificial Randomized Controlled Trials as Topic Recurrence Research Design Syncope, Vasovagal / prevention & control* |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Selecting the appropriate pacing mode for patients with sick sinus syndrome: evidence from randomize...
Next Document: Pacing for vasovagal syncope after the second Vasovagal Pacemaker Study (VPS II): a matter of judgem...